Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more ...

Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...

March 9 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of showing a statistically significant reduction in focal onset seizures in a late-stage trial ...

Epileptic seizures alter sleep by prolonging the stage that's central to memory formation, potentially predisposing the brain ...

A new experimental drug is showing remarkable promise for children with Dravet syndrome, a severe genetic form of epilepsy.

EpiWatch, the first FDA-cleared seizure detection app for Apple Watch, provides seizure detection, alerting and ...

An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.

Xenon Pharmaceuticals released positive topline results from a phase three study of its azetukalner drug for focal onset seizures. The study met its primary endpoint for median percent change in ...

Many patients suffer from epilepsy that cannot be controlled by current medications. Surgical removal of epileptogenic brain regions is effective in only about half of cases, and not all patients are ...

Researchers have discovered that mutations in the FOXJ3 gene act as a "master switch" failure, disrupting how the brain ...

Children whose mothers had diabetes during pregnancy had a higher risk for developing epilepsy during childhood, according to a study published in Pediatrics.“Our findings highlight that prenatal ...

Many families face the challenge of drug-resistant epilepsy, questioning the transition from medication to surgery.